QDx Pathology to Market Mitomics' PCR-Based Mitochondrial DNA Prostate Cancer Test in US
May 19, 2011
QDx Pathology to Market Mitomics' PCR-Based Mitochondrial DNA Prostate Cancer Test in US
The test, which QDx Pathology will market under the name QPredict Prostate Mitomic Test, is based on Mitomics' currently marketed Prostate Core Mitomic Test.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Dx Focus: Akonni TruDiagnosis Studies; Spartan Bio CYP2C19 Test; Mitomics Prostate Cancer Assay
January 10, 2013 / PCR Insider - Dx Focus: LabMD to Distribute Mitomics' Prostate Test; Lab21's NSCLC Companion Dx Test
February 16, 2012 / PCR Insider - Mitomics, QDx Ink Development, Marketing Pact
May 19, 2011 / GenomeWeb Daily News - Cepheid, OHSU Co-developing Cancer MDx Tests for GeneXpert
February 19, 2013 / GenomeWeb Daily News - Q&A: UMich's Arul Chinnaiyan on Discovery, qPCR Validation of Long Non-Coding RNAs
February 7, 2013 / PCR Insider